How the NHS Decides Who Gets the Latest Wonder Drugs
The first rise in NICE's cost-effectiveness threshold in twenty years marks a turning point in how Britain funds life-extending treatments, but significant questions remain about whether the system can deliver.
By
Distilled Post Editorial Team